NDUFV2
ENSG00000178127
Target class
Enzyme
Chromosome
18
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CI-24k
- Target name
- NDUFV2
- Gene name
- NADH:ubiquinone oxidoreductase core subunit V2
- Gene symbol
- NDUFV2
- Protein name
- NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (NDUFV2) (EC 7.1.1.2) (NADH-ubiquinone oxidoreductase 24 kDa subunit)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 143.36
- Tissue specificity (Gini)
- 0.183
- Tissue specificity (tau)
- 0.579
- KEGG gene identifiers
- hsa:4729
- Protein interaction confidence
- 0.915143
- Protein interaction partners
- 133
- R-HSA-611105
- R-HSA-6799198
- End position
- 9134346
- Start position
- 9102433
- Chromosome
- 18
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- Cytosol
- Mitochondria
- Nucleoplasm
- Tissue specificity (tau)
- 0.578954
- Expression inequality (Gini)
- 0.18342
Expression in transcripts per million
- Muscle - Skeletal
- 143.36
- Cells - EBV-transformed lymphocytes
- 138.15
- Heart - Left Ventricle
- 111.36
- Liver
- 99.09
- Adrenal Gland
- 86
Expression in transcripts per million
- Muscle - Skeletal143.36
- Cells - EBV-transformed lymphocytes138.15
- Heart - Left Ventricle111.36
- Liver99.09
- Adrenal Gland86
- Esophagus - Muscularis85.54
- Kidney - Medulla82.22
- Cells - Cultured fibroblasts80.28
- Heart - Atrial Appendage79.86
- Esophagus - Gastroesophageal Junction78.23
- Colon - Sigmoid76
- Esophagus - Mucosa72.47
- Testis67.99
- Brain - Cerebellar Hemisphere67.74
- Artery - Tibial67.5
- Lung65.19
- Nerve - Tibial63.16
- Colon - Transverse62.65
- Brain - Frontal Cortex (BA9)62.18
- Adipose - Subcutaneous62.06
- Bladder62.04
- Artery - Coronary61.41
- Artery - Aorta61.29
- Stomach60.69
- Breast - Mammary Tissue60.6
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0007399
- GO:0048738
- GO:0005739
- GO:0005743
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor